

September 19, 2017

BioNTech AG to Present at Cantor Fitzgerald Healthcare Conference

Mainz, Germany, September 19, 2017 – BioNTech AG, a fully integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that Sean Marett, COO of BioNTech, will be presenting at the Cantor Fitzgerald Healthcare Conference that is being held in New York, NY from September 25-27, 2017. The presentation is scheduled for Tuesday, September 26 at 2:50 PM Eastern Daylight Time.

Mr. Marett will provide an overview of the Company's strategy and its most recent substantial progress, including an update of its clinical pipeline, an overview of its strategic collaborations and a summary of its most recent *Nature* publication related to its neo-epitope based individualized mRNA cancer immunotherapeutic.

For more information, please contact:

General Inquiries:

BioNTech AG

Regina Jehle

Tel: +49 6131 9084 1273

Email: Regina.Jehle@biontech.de

US Media & Investors:

ICR Healthcare

James Heins / Stephanie Carrington

Tel: +1 203 682 8251

Tel: +1 646 277 1282

Email: James.Heins@icrinc.com

Email: Stephanie.Carrington@icrinc.com

International Media & Investor Inquiries:

akampion

Dr. Ludger Wess / Ines-Regina Buth

Tel: +49 40 8816 5964

Tel: +49 30 2363 2768

Email: info@akampion.com

About BioNTech AG

BioNTech is Europe's largest privately held biopharmaceutical company pioneering the development of individualized therapies for treatment of cancer and other diseases. The company combines all building blocks for individualized immunotherapy under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based medicines through innovative chimeric antigen receptors and T-cell receptor-based products to novel bispecific antibody-based immunomodulators. BioNTech's approach is validated by five top-tier corporate partnerships with Genentech, Genmab, Eli Lilly and Company, Sanofi and Bayer Animal Health. Founded in 2008, BioNTech's financial shareholders include the MIG Fonds, Salvia and the Strüngmann Family Office, with the Strüngmann Family Office as the majority shareholder.

More information about BioNTech is available at www.biontech.de.